Eli Lilly is trading 4.03% up at ARS 34560.00, outperforming a weaker broader market as investors rotate toward defensive healthcare stocks.

  • Healthcare has attracted renewed investor interest amid technology-sector volatility, improving earnings expectations, and attractive valuations.
  • A Canada Revenue Agency audit disclosed on August 17, 2026, concerning suspected transfer-pricing issues remains a potential overhang; no public wrongdoing finding has been made.